ClinicalTrials.gg
CompletedNCT02732639Updated Aug 26, 2016Results posted

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

A Phase 3 interventional study of Pegylated Interferon (PEG-IFN) alfa-2a in Hepatitis D, Chronic, sponsored by Hoffmann-La Roche. Completed at 7 sites in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-26.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Hepatitis D, Chronic with a site in Romania — 3 open to participants now, 7 under way, 3 of them phase 3. Hepatitis D, Chronic · Romania.

Started
2005
the only one that year
Phase 3
3 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
2 of 11
Hoffmann-La Roche

Among the 11 studies in Hepatitis D, Chronic with a site in Romania, this one is the only one that started in 2005, is one of 3 in phase 3, and was the 2nd registered.

Hepatitis D, Chronic

43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.

Browse Hepatitis D, Chronic studies →

Open to participants now

3 of the 11 studies in Hepatitis D, Chronic with a site in Romania are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 6 Hepatitis D, Chronic studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Hepatitis D, Chronic with a site in Romania, or all of them as a file.
02

Study summary

This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD). Treatment was followed by 24 weeks of treatment-free follow-up.

03

Conditions studied

  • Hepatitis D, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive surface antigen (HBsAg) for at least 6 months prior to screening
  • Positive anti-delta for at least 3 months prior to screening
  • Positive hepatitis D virus (HDV) ribonucleic acid (RNA)
  • A liver obtained within the past 18 months for non-cirrhotic patients and 30 months for cirrhotic patients demonstrating liver disease consistent with chronic hepatitis D (CHD)
  • Negative urine or serum pregnancy test (for women of ) documented within the 24-hour period prior to the first dose of test drug

Exclusion criteria

Exclusion Criteria:

  • Antiviral therapy for CHD within the previous 6 months
  • Positive hepatitis A, , or (HIV)
  • Evidence of decompensated liver disease
  • Other medical condition associated with chronic liver disease
  • Women with ongoing pregnancy or who are breast feeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Pegylated Interferon (PEG-IFN) alfa-2a

    Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.

    Drug: Pegylated Interferon (PEG-IFN) alfa-2a

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72

    Samples were collected and analyzed for ALT. A normal ALT is a value within the normal range of the assay.

    Time frame: At Week 72

  2. Percentage of Participants With Negative Hepatitis D Virus Ribonucleic Acid (HDV RNA) at Week 72

    Samples were collected and analyzed for HDV RNA levels. Negative HDV RNA is defined as below the level of detection of the assay.

    Time frame: At Week 72

Secondary outcomes

  1. Percentage of Participants With Normal ALT at Week 48

    Samples were collected and analyzed for ALT levels. A normal ALT is a value within the normal range of the assay.

    Time frame: At Week 48

  2. Percentage of Participants With Negative HDV RNA at Week 48

    Samples were collected and analyzed for HDV RNA levels. Negative HDV RNA is defined as below the level of detection of the assay.

    Time frame: At Week 48

  3. Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Below 1*10^5 Copies/Milliliter (mL) at Weeks 48 and 72

    Samples were collected and analyzed for HBV DNA levels. Reported here is the percentage of participants with HBV DNA levels below 1\*10\^5 copies/mL.

    Time frame: At Weeks 48 and 72

  4. Number of Participants With Positive Hepatitis B Surface Antigen (HBsAg) Levels

    Samples were collected and analyzed for HBsAg. Positive HBsAg levels are defined as levels above the level of detection of the assay.

    Time frame: At Screening and at Weeks 48 and 72

  5. Percentage of Participants With HBsAg Seronegative at Weeks 48 and 72

    Samples were collected and analyzed for HBsAg. Seronegative HBsAg is defined as below the level of detection of the assay.

    Time frame: At Weeks 48 and 72

  6. Percentage of Participants With Positive Hepatitis B Surface Antibody (HBsAb) at Weeks 48 and 72

    Samples were collected and analyzed for HBsAb. Positive HBsAb levels are defined as levels above the level of detection of the assay and reflect the presence of antibodies produced against HBsAg.

    Time frame: At Weeks 48 and 72

07

Results

Posted Aug 26, 2016

Participant flow

Participant flow — Overall Study
MilestonePegylated Interferon (PEG-IFN) Alfa-2a
Started31
Completed30
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72

Samples were collected and analyzed for ALT. A normal ALT is a value within the normal range of the assay.

Time frame:
At Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72
percentage of participantsPegylated Interferon (PEG-IFN) Alfa-2a
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 7254.84 (37.3 to 72.4)
PrimaryPercentage of Participants With Negative Hepatitis D Virus Ribonucleic Acid (HDV RNA) at Week 72

Samples were collected and analyzed for HDV RNA levels. Negative HDV RNA is defined as below the level of detection of the assay.

Time frame:
At Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With Negative Hepatitis D Virus Ribonucleic Acid (HDV RNA) at Week 72
percentage of participantsPegylated Interferon (PEG-IFN) Alfa-2a
Percentage of Participants With Negative Hepatitis D Virus Ribonucleic Acid (HDV RNA) at Week 7261.29 (44.1 to 78.4)
SecondaryPercentage of Participants With Normal ALT at Week 48

Samples were collected and analyzed for ALT levels. A normal ALT is a value within the normal range of the assay.

Time frame:
At Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 48
percentage of participantsPegylated Interferon (PEG-IFN) Alfa-2a
Percentage of Participants With Normal ALT at Week 4845.16 (27.6 to 62.7)
SecondaryPercentage of Participants With Negative HDV RNA at Week 48

Samples were collected and analyzed for HDV RNA levels. Negative HDV RNA is defined as below the level of detection of the assay.

Time frame:
At Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Negative HDV RNA at Week 48
percentage of participantsPegylated Interferon (PEG-IFN) Alfa-2a
Percentage of Participants With Negative HDV RNA at Week 4864.52 (47.7 to 81.4)
SecondaryPercentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Below 1*10^5 Copies/Milliliter (mL) at Weeks 48 and 72

Samples were collected and analyzed for HBV DNA levels. Reported here is the percentage of participants with HBV DNA levels below 1\*10\^5 copies/mL.

Time frame:
At Weeks 48 and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Below 1*10^5 Copies/Milliliter (mL) at Weeks 48 and 72
percentage of participantsPegylated Interferon (PEG-IFN) Alfa-2a
HBV-DNA at Week 4883.87 (70.9 to 96.8)
HBV-DNA at Week 7274.19 (58.8 to 89.6)
SecondaryNumber of Participants With Positive Hepatitis B Surface Antigen (HBsAg) Levels

Samples were collected and analyzed for HBsAg. Positive HBsAg levels are defined as levels above the level of detection of the assay.

Time frame:
At Screening and at Weeks 48 and 72
Reported as:
Number · participants
Number of Participants With Positive Hepatitis B Surface Antigen (HBsAg) Levels
participantsPegylated Interferon (PEG-IFN) Alfa-2a
HBsAg Positive at Screening31
HBsAg Positive at Week 4829
HBsAg Positive at Week 7226
SecondaryPercentage of Participants With HBsAg Seronegative at Weeks 48 and 72

Samples were collected and analyzed for HBsAg. Seronegative HBsAg is defined as below the level of detection of the assay.

Time frame:
At Weeks 48 and 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seronegative at Weeks 48 and 72
percentage of participantsPegylated Interferon (PEG-IFN) Alfa-2a
Seronegative HBsAg at Week 480 (NA to NA)
Seronegative HBsAg at Week 723.23 (0.0 to 9.4)
SecondaryPercentage of Participants With Positive Hepatitis B Surface Antibody (HBsAb) at Weeks 48 and 72

Samples were collected and analyzed for HBsAb. Positive HBsAb levels are defined as levels above the level of detection of the assay and reflect the presence of antibodies produced against HBsAg.

Time frame:
At Weeks 48 and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Hepatitis B Surface Antibody (HBsAb) at Weeks 48 and 72
percentage of participantsPegylated Interferon (PEG-IFN) Alfa-2a
Positive HBsAb at Week 483.23 (0.0 to 9.4)
Positive HBsAb at Week 723.23 (0.0 to 9.4)

Adverse events

Collected over Up to week 72. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegylated Interferon (PEG-IFN) Alfa-2a———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pegylated Interferon (PEG-IFN) Alfa-2a
Mean38 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Pegylated Interferon (PEG-IFN) Alfa-2a
Female10
Male21
08

Study locations

7 sites
  • Bucharest, 021105, Romania
  • Bucharest, 022328, Romania
  • Cluj-napoca, 400162, Romania
  • Constanta, Romania
  • Craiova, Romania
  • Iasi, 700111, Romania
  • Timisoara, 293406, Romania
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 7 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2016
First posted
Apr 8, 2016
Start
Oct 2005
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Aug 26, 2016
Last update
Aug 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02732639
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 8, 2016
Start date
Oct 2005
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Aug 26, 2016
Last update
Aug 26, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion